NCT04268290

Brief Summary

Conventional laparoscopic surgery (CLS) for colorectal cancer has been demonstrated to be safe and feasible and present minimally invasive benefits including faster recovery, reduced postoperative pain and shorter hospital stay, also acquiring comparable oncologic outcomes with open surgery. To achieve further minimally invasive outcomes, SILS plus one port surgery was attempted by some surgeons. Preliminary results showed that SILS+1 could achieve better minimally invasive benefits than CLS while preserving oncologic feasibility. Till now, ERAS has been practiced in colorectal cancer surgery for approximately 20 years. Studies have proven that ERAS is safe and significantly improved the recovery course of patients during perioperative period, meanwhile, the expense could be greatly reduced. Based on ERAS studies protocols and SILS+1 trials, investigators tried to combine SILS+1 with ERAS, hopefully to provide patients with more safe, economic, feasible and rapid surgery and perioperative strategies.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P75+ for phase_2 colorectal-cancer

Timeline
Completed

Started Feb 2020

Shorter than P25 for phase_2 colorectal-cancer

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 25, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 13, 2020

Completed
2 days until next milestone

Study Start

First participant enrolled

February 15, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2022

Completed
Last Updated

February 13, 2020

Status Verified

November 1, 2019

Enrollment Period

2 years

First QC Date

December 25, 2019

Last Update Submit

February 12, 2020

Conditions

Keywords

Colorectal CancerERASSingle Incision plus oneLaparoscopic surgery

Outcome Measures

Primary Outcomes (2)

  • Rehabilitative rate

    The percentage of patients who met discharge criteria in the fourth day after surgery

    4 days

  • Postoperative hospital stays

    Days from surgery to discharge

    1 month

Secondary Outcomes (8)

  • Medical cost

    1 month

  • Postoperative pain score

    Once a day from 6 hours to the fourth day after surgery

  • Postoperative recovery index

    1 month

  • Postoperative inflammatory immune response

    3 days

  • compliance with ERAS measures

    perioperative

  • +3 more secondary outcomes

Study Arms (1)

SILS plus one assistant ERAS

EXPERIMENTAL

Preoperative: preadmission information, education, counseling, optimization ( breathing training), shortening fasting time and carbohydrate load Intraoperative: The intravenous fluid therapy is restricted. All patients undergo single incision plus one port laparoscopic surgery(SILS plus one). A suitable warming device (such as forced-air heating blankets) and warmed intravenous fluids are been adopted routinely to keep body temperature Postoperative: multimodal analgesia (surgical site infiltration, a nonsteroidal anti-inflammatory drug, epidural analgesia) early oral intake and move. nasogastric tubes should not be used routinely. Nasogastric tubes inserted during surgery are been removed before reversal of an aesthesia.

Combination Product: Single incision plus one port laparoscopic surgery

Interventions

SILS plus one port surgery and enhanced recovery after surgery protocol both are methods taking the minimally invasive benefits for the patients including faster recovery, reduced postoperative pain and shorter hospital stay.

Also known as: The program of enhanced recovery After Surgery
SILS plus one assistant ERAS

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Primary tumor diagnosed as adenocarcinoma confirmed pathologically by endoscopic biopsy
  • cT1-4a, N0-3, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual Seventh Edition
  • Located in the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, the upper segment of the rectum.
  • Diameter ≦ 5cm
  • No severe organ dysfunction
  • Performance status of 0 or 1 on ECOG (Eastern Cooperative Oncology Group) scale
  • ASA (American Society of Anesthesiology) score class I or II
  • Written informed consent

You may not qualify if:

  • Unsuitable for patients undergoing single incision plus one port laparoscopic surgery
  • Patients with Complications caused by colorectal cancer ( bleeding , perforation, obstruction or incomplete obstruction )
  • Previous abdominal surgery
  • Malignant diseases within the past 5years
  • Requirements of simultaneous surgery for another diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Zhang X, Li G, Li X, Liang Z, Lan X, Mou T, Xu Z, Fu J, Wu M, Li G, Wang Y. Effect of single-incision plus one port laparoscopic surgery assisted with enhanced recovery after surgery on colorectal cancer: study protocol for a single-arm trial. Transl Cancer Res. 2021 Dec;10(12):5443-5453. doi: 10.21037/tcr-21-1361.

MeSH Terms

Conditions

Colorectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Wang Yannan, M.D

    Nanfang Hospital, Southern Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wang Yanan, M.D

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 25, 2019

First Posted

February 13, 2020

Study Start

February 15, 2020

Primary Completion

February 15, 2022

Study Completion

February 15, 2022

Last Updated

February 13, 2020

Record last verified: 2019-11